Compare MSLE & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MSLE | SGMT |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.9M | 169.4M |
| IPO Year | N/A | 2021 |
| Metric | MSLE | SGMT |
|---|---|---|
| Price | $7.30 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.38 |
| AVG Volume (30 Days) | 104.5K | ★ 296.4K |
| Earning Date | N/A | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.67 | $1.73 |
| 52 Week High | $13.39 | $11.41 |
| Indicator | MSLE | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 32.85 | 33.31 |
| Support Level | $6.67 | N/A |
| Resistance Level | $8.37 | $6.62 |
| Average True Range (ATR) | 0.84 | 0.25 |
| MACD | -0.25 | -0.07 |
| Stochastic Oscillator | 12.01 | 0.74 |
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.